Compare Diageo plc (DEO) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Enveric Biosciences Inc — how do they compare? Diageo plc trades at $87.58 (market cap $47.54B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Diageo plc is far larger — about 7106.1× Enveric Biosciences Inc's market cap, and Diageo plc pays a 2.36% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Enveric Biosciences Inc for 14 Days on average.
| DEO | ENVB | |
|---|---|---|
Market Cap | $47.54B | $6.69M |
Volume | 1,824,704 | 41,141 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $10.80 |
52-Week Low | $72.47 | $1.27 |
Typical Hold Time | 66 Days | 14 Days |
Enterprise Value | $67.96B | -$1.60M |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down slightly by 0.06% on the day, with a bearish technical signal from moving averages. The company shows solid profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027, while analyst consensus leans positive with 49% buy ratings.
The outlook is mixed: cost-cutting and brand investments support a turnaround, but declining 2026 revenue and net income projections pose risks. Valuation ratios like P/E of 27.19 suggest premium pricing, requiring execution success to justify. Key risks include U.S. market challenges and regulatory scrutiny in regions like India.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
